GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

HSK31858   Click here for help

GtoPdb Ligand ID: 13959

Synonyms: compound 54 [PMID: 34374541]
Compound class: Synthetic organic
Comment: HSK31858 (Haisco, Chiesi) is an irreversible, oral dipeptidyl peptidase-1 inhibitor (DPP-1; cathepsin C) inhibitor [1].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 7
Hydrogen bond donors 2
Rotatable bonds 6
Topological polar surface area 67.62
Molecular weight 463.89
XLogP 1.47
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CN1CCN(CC1)C2=CC=C(N=C2)NC3=NC(=C(C=N3)Cl)NC4=CC(=CC=C4)C(F)(F)F
Isomeric SMILES CN1CCN(CC1)C2=CN=C(NC3=NC=C(Cl)C(NC4=CC(=CC=C4)C(F)(F)F)=N3)C=C2
InChI InChI=1S/C21H21ClF3N7/c1-31-7-9-32(10-8-31)16-5-6-18(26-12-16)29-20-27-13-17(22)19(30-20)28-15-4-2-3-14(11-15)21(23,24)25/h2-6,11-13H,7-10H2,1H3,(H2,26,27,28,29,30)
InChI Key JNAOGJWOQFVLOM-UHFFFAOYSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

No information available.
Summary of Clinical Use Click here for help
HSK31858 is a clinical lead for neutrophil-mediated chronic inflammatory diseases.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT05663593 Safety, Tolerability,PK/PD, Food Effect of Single and Multiple Ascending Doses of HSK31858 in Healthy Volunteers Phase 1 Interventional Haisco Pharmaceutical Group Co., Ltd. 2
NCT06637254 A Study to Evaluate the Efficacy and Safety of HSK31858 Tablets in Patients with Bronchial Asthma Phase 2 Interventional Haisco Pharmaceutical Group Co., Ltd.
NCT06660992 A Study to Assess the Efficacy and Safety of HSK31858 in Participants With Non-Cystic Fibrosis Bronchiectasis Phase 3 Interventional Haisco Pharmaceutical Group Co., Ltd.
NCT05601778 A Study of HSK31858 in Participants with Non-Cystic Fibrosis Bronchiectasis Phase 2 Interventional Haisco Pharmaceutical Group Co., Ltd. 3